Syngene International Ltd
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations. [1]
- Market Cap ₹ 17,560 Cr.
- Current Price ₹ 435
- High / Low ₹ 679 / 344
- Stock P/E 66.0
- Book Value ₹ 120
- Dividend Yield 0.28 %
- ROCE 9.99 %
- ROE 7.78 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 3.67 times its book value
- The company has delivered a poor sales growth of 11.4% over past five years.
- Company has a low return on equity of 10.2% over last 3 years.
- Dividend payout has been low at 12.0% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 860 | 1,107 | 1,201 | 1,423 | 1,826 | 2,012 | 2,184 | 2,604 | 3,193 | 3,489 | 3,642 | 3,739 | 3,522 | |
| Sales growth | +23% | +29% | +8% | +28% | +10% | +9% | +19% | +23% | +9% | +4% | +3% | -6% | |
| 579 | 727 | 816 | 949 | 1,289 | 1,394 | 1,507 | 1,861 | 2,251 | 2,472 | 2,598 | 2,817 | 2,772 | |
| Operating Profit | 281 | 380 | 385 | 474 | 537 | 618 | 678 | 743 | 942 | 1,017 | 1,045 | 921 | 751 |
| OPM % | 33% | 34% | 32% | 33% | 29% | 31% | 31% | 29% | 30% | 29% | 29% | 25% | 21% |
| 12 | 6 | 94 | 53 | 75 | 153 | 94 | 75 | 63 | 77 | 101 | -9 | -6 | |
| Interest | 8 | 8 | 18 | 23 | 32 | 35 | 28 | 24 | 45 | 47 | 53 | 49 | 44 |
| Depreciation | 81 | 97 | 114 | 131 | 164 | 219 | 274 | 310 | 366 | 426 | 433 | 453 | 449 |
| Profit before tax | 204 | 281 | 346 | 372 | 415 | 517 | 469 | 484 | 594 | 621 | 660 | 411 | 252 |
| Tax % | 14% | 14% | 17% | 18% | 20% | 20% | 14% | 18% | 22% | 18% | 25% | 23% | |
| 175 | 241 | 287 | 305 | 332 | 412 | 405 | 396 | 464 | 510 | 496 | 317 | 186 | |
| EPS in Rs | 4.38 | 6.02 | 7.18 | 7.64 | 8.29 | 10.30 | 10.12 | 9.88 | 11.57 | 12.69 | 12.33 | 7.86 | 4.62 |
| Dividend Payout % | 239% | 8% | 7% | 7% | 3% | 0% | 0% | 10% | 11% | 10% | 10% | 16% |
(S): Standalone figures, shown where consolidated figures are not available.
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 11% |
| 3 Years: | 5% |
| TTM: | -6% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 0% |
| 3 Years: | -8% |
| TTM: | -43% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | -6% |
| 3 Years: | -16% |
| 1 Year: | -32% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 11% |
| 3 Years: | 10% |
| Last Year: | 8% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 199 | 200 | 200 | 200 | 200 | 400 | 400 | 401 | 401 | 402 | 402 | 403 | 404 |
| Reserves | 646 | 825 | 1,213 | 1,520 | 1,768 | 1,776 | 2,421 | 2,897 | 3,217 | 3,856 | 4,324 | 4,436 | 4,455 |
| 155 | 891 | 806 | 787 | 813 | 773 | 893 | 1,022 | 815 | 555 | 578 | 458 | 507 | |
| 422 | 440 | 555 | 681 | 922 | 1,214 | 1,169 | 1,245 | 1,398 | 1,339 | 1,491 | 1,757 | 1,292 | |
| Total Liabilities | 1,422 | 2,356 | 2,775 | 3,189 | 3,704 | 4,163 | 4,883 | 5,564 | 5,831 | 6,152 | 6,796 | 7,055 | 6,658 |
| 503 | 580 | 810 | 1,030 | 1,377 | 2,020 | 2,201 | 2,393 | 2,667 | 2,850 | 2,802 | 3,000 | 2,880 | |
| CWIP | 105 | 237 | 175 | 155 | 274 | 234 | 237 | 346 | 177 | 838 | 1,266 | 1,046 | 1,141 |
| Investments | 146 | 277 | 540 | 158 | 716 | 776 | 702 | 1,034 | 918 | 548 | 647 | 741 | 610 |
| 667 | 1,262 | 1,249 | 1,846 | 1,337 | 1,133 | 1,743 | 1,790 | 2,069 | 1,916 | 2,081 | 2,268 | 2,028 | |
| Total Assets | 1,422 | 2,356 | 2,775 | 3,189 | 3,704 | 4,163 | 4,883 | 5,564 | 5,831 | 6,152 | 6,796 | 7,055 | 6,658 |
(S): Standalone figures, shown where consolidated figures are not available.
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18 | 308 | 398 | 446 | 630 | 677 | 701 | 581 | 824 | 1,042 | 1,168 | 915 | |
| 16 | -753 | -470 | -349 | -646 | -424 | -629 | -611 | -653 | -494 | -744 | -839 | |
| -10 | 716 | -81 | -79 | -72 | -226 | 58 | -31 | -342 | -551 | -142 | -215 | |
| Net Cash Flow | 24 | 272 | -153 | 18 | -88 | 28 | 130 | -62 | -172 | -4 | 281 | -138 |
| Free Cash Flow | -178 | 16 | 92 | 82 | 47 | 34 | 255 | 105 | 305 | 553 | 398 | 547 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 22% | 92% | 123% | 111% | 135% | 127% | 116% | 92% | 102% | 115% | 123% | 107% |
(S): Standalone figures, shown where consolidated figures are not available.
Ratios
Consolidated / View Standalone
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 76 | 61 | 60 | 68 | 68 | 72 | 79 | 71 | 61 | 46 | 53 | 50 |
| Inventory Days | 59 | 44 | 37 | 82 | 30 | 18 | 41 | 87 | 141 | 94 | 60 | 56 |
| Days Payable | 106 | 87 | 116 | 195 | 154 | 156 | 167 | 113 | 109 | 100 | 136 | 138 |
| Cash Conversion Cycle | 29 | 18 | -19 | -44 | -56 | -66 | -47 | 45 | 92 | 40 | -23 | -32 |
| Working Capital Days | -64 | -65 | -44 | -48 | -103 | -172 | -66 | -43 | -14 | -27 | -51 | -68 |
| ROCE % | 23% | 20% | 18% | 17% | 17% | 14% | 13% | 15% | 15% | 13% | 10% |
(S): Standalone figures, shown where consolidated figures are not available.
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Active Clients clients |
|
|||||||||||
| R&D and Manufacturing Infrastructure Million sq. ft. |
||||||||||||
| Number of Scientists scientists |
||||||||||||
| Total Headcount employees |
||||||||||||
| Patents Held with Clients patents |
||||||||||||
| PhDs in Workforce PhDs |
||||||||||||
| Client and Regulator Audits audits |
||||||||||||
| Research Services Share of Revenue % |
||||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- Intimation of Schedule of Meetings with Analyst/Institutional Investor(s)
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- Syngene schedules analyst/investor meetings with several institutions from 17-24 Nov 2026.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- Syngene uploaded Q2 FY2027 earnings conference call transcript on its website.
- Announcement under Regulation 30 (LODR)-Newspaper Publication
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- Audio recording of Syngene’s Q2 FY27 earnings call uploaded on October 28, 2026.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
Concalls
-
Oct 2026Transcript PPT REC
-
Jul 2026Transcript PPT REC
-
Apr 2026Transcript PPT REC
-
Jan 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Sep 2025PPT
-
Jul 2025Transcript PPT
-
Apr 2025Transcript REC
-
Mar 2025PPT
-
Jan 2025Transcript PPT REC
-
Oct 2024Transcript PPT
-
Jul 2024Transcript PPT REC
-
Apr 2024Transcript
-
Jan 2024Transcript PPT
-
Oct 2023Transcript PPT
-
Jul 2023Transcript PPT
-
May 2023Transcript PPT
-
Jan 2023Transcript PPT
-
Oct 2022PPT
-
Jul 2022PPT
-
Apr 2022PPT
-
Jan 2022Transcript PPT
-
Oct 2021Transcript PPT
-
Jul 2021Transcript PPT
-
Apr 2021PPT
-
Mar 2021Transcript
-
Jan 2021PPT
-
Oct 2020Transcript PPT
-
Jul 2020Transcript PPT
-
May 2020Transcript PPT
-
Feb 2020Transcript
-
Jan 2020PPT
-
Dec 2019Transcript
-
Oct 2019Transcript PPT
-
Jul 2019Transcript PPT
-
Apr 2019Transcript PPT
-
Feb 2019Transcript PPT
-
Oct 2018Transcript PPT
-
Jul 2018PPT
-
May 2018Transcript
-
Apr 2018Transcript PPT
-
Jan 2018PPT
-
Nov 2017Transcript PPT
-
Aug 2017Transcript PPT
-
May 2017Transcript PPT
-
Jan 2017PPT
-
Oct 2016PPT
-
Jul 2016PPT
-
Feb 2016PPT
-
Oct 2015Transcript
Business Footprint:[1]
The company caters to diverse end-user industries like Pharmaceuticals, Animal Health, Agrochemicals, Consumer Packaged Goods, Chemicals/Polymers. It has 400+ active customers with engagements with 13 out of the top 15 global pharma companies. The company holds 400+ patents jointly with clients and has a base of 6000+ scientists.